Posts by Meng-Ju Wu, PhD
-
Novel Strategy Proposed To Enhanced Treatment of Cholangiocarcinoma With IDH1 Mutations
Meng-Ju Wu, PhD, Nabeel Bardeesy, PhD, Robert Manguso PhD, and colleagues found in a mouse model of cholangiocarcinoma that immune function and the interferon-gamma/TET2 axis are essential for response to mutant IDH1 inhibitors, and they suggest a novel strategy for boosting the efficacy of these inhibitors.
Biography
Meng-Ju Wu, PhD, is a research scientist in the Massachusetts General Hospital Cancer Center and an instructor in medicine at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.